-
Initial Description
Swiss physician Gaspard Vieusseux first describes meningococcal disease, following an epidemic in Geneva, Switzerland. -
Neisseria meningitidis
Anton Weichselbaum discovers bacterial Neisseria meningitidis the bacteria that causes meningococcal disease, in patients affected by meningitis -
outbreak
Major epidemic outbreaks are observed in Africa, especially in the sub-Saharan region. -
Simon Flexnor
American scientist Simon Flexner develops an antimeningococcal serum that is shown to decrease mortality in people with meningococcal meningitis. -
penicillin
Penicillin is used for the first time to treat patients who have meningococcal meningitis -
polysaccharide vaccine
The first polysaccharide vaccine for meningococcal meningitis is approved, but it only protects against 1 of the 5 serogroups -
one of the first meningitis vaccines against 4 out of 5 serogroups
The first meningococcal disease vaccine to help protect against 4 of the 5 major serogroups of meningococcal bacteria is licensed in the United States -
all recruits vaccinated
The US Army begins to vaccinate all recruits against meningococcal disease. This came following several outbreaks that led to the development of polysaccharide vaccines. -
epidemic
More than 25,000 people die during the largest meningococcal meningitis epidemic ever recorded in history. More than 250,000 cases are reported. -
fight
organizations draw up a plan for the development of conjugate vaccines to fight and eliminate meningitis epidemics in Africa. -
FDA takes action
The FDA licenses additional meningococcal disease vaccines, called meningococcal conjugate vaccines, to help protect against 4 of the 5 major disease-causing serogroups. -
Preteen vaccinations
The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for preteens against meningococcal disease at the 11- to 12-year-old checkup. -
MCV4-CRM Vaccine
MCV4-CRM (Meningitis vaccine) is approved by FDA for children from ages 2-23 months
